Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

计划入组 390 人 · 首次发布于 2024 年 9 月 19 日

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

计划入组 15 人 · 首次发布于 2018 年 3 月 12 日

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

计划入组 30 人 · 首次发布于 2015 年 9 月 30 日

PIV5-MERS-S

Parainfluenza Virus(Meissa Vaccines)

Oral Polio Vaccine

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Clover Biopharmaceuticals Reports Positive Phase I Data for First-in-Class RSV-hMPV-PIV3 Combination Vaccines

Clover Biopharmaceuticals Advances RSV Vaccine SCB-1019 with U.S. IND Clearance for Revaccination Study

Sanofi Acquires Vicebio for $1.15 Billion to Expand Respiratory Vaccine Pipeline with Molecular Clamp Technology